- Mechanism
- Stimulates pulsatile GH release via GHRH receptor
- Typical research dose
- 100-300 mcg/dose subcutaneous
- Route
- subcutaneous
- Half-life
- ~30 minutes
- Legal status
- Research Only
Overview
The CJC-1295 (No DAC/Mod GRF 1-29) peptide is a synthetic, 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH). It binds to pituitary receptors to stimulate the natural, pulsatile secretion of growth hormone and insulin-like growth factor 1 (IGF-1). By preserving the body's natural hormone rhythms while extending the half-life of standard GHRH, it offers a highly controlled mechanism for researchers. Understanding CJC-1295 (No DAC/Mod GRF 1-29) benefits is crucial for advancing clinical models of anti-aging, muscle hypertrophy, and metabolic recovery.
Potential Benefits
- Targeted Fat Loss: Studies suggest GHRH analogs enhance lipolysis, leading to improved lipid metabolism and overall body composition.
- Accelerated Tissue Repair: Elevated IGF-1 levels facilitated by the peptide accelerate the healing of micro-tears in muscle and connective tissues.
- Enhanced Muscle Hypertrophy: Increased growth hormone secretion stimulates protein synthesis, promoting lean muscle growth in animal models.
- Improved Sleep Architecture: Clinical observations link optimized growth hormone pulsatility to increased duration of slow-wave deep sleep.
- Anti-Aging Properties: By restoring youthful growth hormone levels, this peptide may improve skin elasticity and bone mineral density in aging populations.
Where to Buy CJC-1295 (No DAC/Mod GRF 1-29)
Research compound. CJC-1295 (No DAC/Mod GRF 1-29) is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Injection site redness, pain, or swelling
- Transient facial flushing or warmth
- Mild water retention in the extremities
- Temporary numbness or tingling (paresthesia)
- Headaches shortly after administration
Rare or serious side effects:
- Insulin resistance with prolonged, high-dose use
- Carpal tunnel syndrome secondary to fluid retention
- Acromegaly-like symptoms under excessive dosing
- Pituitary gland overstimulation or hyperplasia
CJC-1295 (No DAC/Mod GRF 1-29) is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Receptor binding and activation drive the primary mechanism of the CJC-1295 (No DAC/Mod GRF 1-29) peptide. It selectively binds to the growth hormone-releasing hormone receptor (GHRHR) located on the anterior pituitary gland. This interaction triggers a cAMP-dependent intracellular signaling pathway that stimulates the synthesis and secretion of endogenous growth hormone. Unlike synthetic secretagogues that cause a continuous hormone bleed, this modified peptide preserves the natural pulsatile release of growth hormone.
Enzymatic resistance is achieved through specific amino acid substitutions at positions 2, 8, 15, and 27 of the original GRF 1-29 sequence. These structural modifications protect the peptide chain from rapid degradation by dipeptidyl peptidase-4 (DPP-IV) and other blood plasma enzymes. Consequently, the half-life is extended from mere minutes to approximately 30 minutes, allowing for a more sustained therapeutic window. This optimized pharmacokinetic profile maximizes CJC-1295 (No DAC/Mod GRF 1-29) benefits while minimizing the risk of receptor downregulation.
Origin & History
Discovery and structural evolution of Modified GRF 1-29 emerged from efforts to improve the clinical viability of natural growth hormone-releasing hormone. Researchers identified that the first 29 amino acids of the 44-amino-acid GHRH sequence retained full biological activity, leading to the creation of Sermorelin. To overcome Sermorelin's extremely short half-life, scientists introduced four specific amino acid substitutions, creating what is now known as Mod GRF 1-29. This compound is frequently, though inaccurately, referred to as CJC-1295 without the Drug Affinity Complex (DAC).
Regulatory and research status currently classifies this compound strictly as an investigational research chemical rather than an FDA-approved therapeutic. While the DAC-bound version was developed by ConjuChem to bind with serum albumin for a multi-day half-life, the non-DAC version remains popular in clinical studies requiring short-acting pulsatile stimulation. Ongoing investigations continue to evaluate CJC-1295 (No DAC/Mod GRF 1-29) side effects and long-term safety in anti-aging and metabolic research contexts.